{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-113553","form_type":"8-K","ticker":"NWBO","cik":"0001072379","company_name":"NORTHWEST BIOTHERAPEUTICS INC","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.584636+00:00","generated_at":"2026-05-30T06:48:11.533239+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity","bullets":["Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.","Note matures in 24 months with no payments due until maturity; interest at 11% per annum.","Holder can convert into common stock at $0.30/share or non-dilutive financial instrument priced at $50,000.","Proceeds will be used for ongoing business operations; customary default provisions apply."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-113553","json":"https://secwatch.observer/filing/0001104659-24-113553.json","markdown":"https://secwatch.observer/filing/0001104659-24-113553.md","text":"https://secwatch.observer/filing/0001104659-24-113553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1072379/000110465924113553/0001104659-24-113553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1072379/000110465924113553/tm2420750d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:48:11.533239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}